Immunization

Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Companies seek FDA approval for individuals aged 12 years and older to receive vaccinations for their primary series.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

Ideally, older patients receive vaccinations by October, but disease activity often peaks in February or March.

If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.

One of the major concerns about getting a flu vaccine is its safety for women during pregnancy.

Approximately 48.1% of those who received vaccines had family members or friends who were either sick or recovered from the illness compared with 26.9% who were unvaccinated.

Antibodies from an original COVID-19 vaccination may treat the mRNA booster vaccine as a virus that needs to be cleared.

Findings indicate that primary vaccines can be improved among younger, rural-dwelling individuals.

First season of makeover show follows 5 pharmacies building immunization programs.

US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.

Streptolysin O appears to influence the pathogenesis of Streptococcus group A and direct mutation-mediated virulence in a host.

IQVIA report states that appropriate reimbursement for all health care professionals who provide immunization services would encourage their ongoing provision of vaccines.

COVID-19 vaccines are known to have one of the most complex schedules that the average pharmacist has ever had to manage for a vaccine directed towards a single preventable disease.

Protect patients by evaluating VIGIV concentration and avoiding tearing of metal flange on vaccine vial.

Based on study findings, Moderna plans to submit for regulatory approval in the first half of 2023 for mRNA-1345, a novel vaccine for respiratory syncytial virus.

Independent, scheduled review of Phase 3 Mosaico clinical trial finds a lack of efficacy in preventing the infection.

Viral vector vaccines and a booster can protect maternal women against the Omicron variant of COVID-19, but the mRNA vaccine with a booster dose appears to offer the best protection.

Can the profession afford not to retain expanded job roles for technicians in a post-pandemic era?

Across all vaccines for adults, regardless of income, location, or sex, most of the administration took place in a pharmacy, report shows.

The vaccine was 88% effective at preventing pertussis among infants younger than 2 months when administered during the third trimester of pregnancy.

The risk of severe COVID-19 continues to outweigh the rare risk of post-vaccination myocarditis.

There are currently 33 RSV prevention candidates in clinical development using 6 different approaches.

Relative risk calculations show that vaccinated individuals infected with the first Omicron subvariants of COVID-19 could have protection that lasts nearly 3 seasons.

There have been more than 80,000 monkeypox cases reported worldwide.

The novel antibody will receive expedited review, according to the FDA, and already has market authorization in the European Union.

Pharmacists play a vital role in administering these and educating patients about COVID-19, influenza, pneumococcal, and Tdap vaccinations.

Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.